Simnova announced a Series B of nearly 400 million yuan on August 31 to advance experimental treatments for cancer and autoimmune disease. The Shanghai-based biotech develops cell therapies: treatments that use immune cells, modified to recognize particular targets, to act against disease. Its two main approaches address a difficult practical problem in the field—how to deliver engineered cells without making an entirely separate medicine from each patient's own cells.
One route is an off-the-shelf product. Simnova's SNC103 program uses engineered natural killer cells, a type of immune cell, directed at a marker called CD19 on B cells. The intended workflow is to manufacture and preserve cells in batches for later treatment, rather than begin a new manufacturing cycle whenever an individual patient needs a dose. Simnova's technology page describes donor screening, cell expansion and formulation as parts of that work. Consistent manufacturing is therefore part of the product proposition, alongside what the cells do after administration.
The second route moves the engineering step inside the body. Simnova's SNC116 program uses a viral delivery vehicle to introduce the instructions needed to generate modified T cells in a patient. This is an experimental alternative to collecting cells, modifying them in a separate facility and returning them for treatment. The company says clinical research has begun; that is not an approval or proof that the approach will be safer, cheaper or more effective than established treatments.
The business combines its own development programs with collaboration rights. In January 2025, Simnova and Orna expanded an agreement under which Simnova would develop and commercialize certain RNA-based cell therapies in Greater China, while Orna retained rights elsewhere. The agreement provides for potential milestones and royalties, not evidence that those future payments or product sales have occurred. That partnered RNA work is distinct from the viral-delivery approach described for SNC116. Simnova's own history records a 2021 spinout from Simcere and an earlier Shanghai manufacturing facility.
Fortera Capital, Cenova Capital and Shanghai Pudong Venture Capital co-led the Series B, with other new and existing investors participating. Simnova's announcement, carried by the China Pharmaceutical Innovation and Research Development Association, identifies SNC103 clinical studies and SNC116 development as the main uses of proceeds. The disclosed yuan figure is approximately $59.5 million using the European Central Bank's August 31 reference rates; the company did not disclose an exact round total.
For Simnova, the next business milestone is stronger clinical evidence that can support further development and eventual regulatory review. The company plans additional confirmatory work on SNC103 in 2027. Producing a repeatable batch and engineering cells inside a patient pose different technical challenges, so progress in one program does not validate the other. The financing lets Simnova pursue both, while the central question remains whether either approach can turn a promising treatment design into a consistently usable medicine.